Orthomolekulare Diagnostik, Prävention und Therapie am Beispiel der Omega-3-Fettsäuren und ihrer Metabolite

Zusammenfassung

Die Therapie mit Omega-3-Fettsäuren, insbesondere Eicosapentaensäure (EPA) und Docosahexaensäure (DHA), hat in den letzten 10 Jahren einen festen Stellenwert in der Behandlung kardiovaskulärer Erkrankungen sowie chronisch entzündlicher Erkrankungen mit autoimmuner Komponente gefunden. Auf der Basis eines Fettsäurestatus ist ein gezielter Einsatz dieser Substanzen möglich. Omega-3-Fettsäuren sind Ausgangspunkt einer Vielzahl von Metaboliten, deren Funktionsweise in den letzten Jahren aufgeklärt werden konnte. Nicht nur die Modulation von Cyclooxygenase- und Lipoxygenasewirkungen bestimmt die therapeutische Aktivität der Omega-3-Fettsäuren, sondern vielmehr auch neu entdeckte Substanzen wie Lipoxine, Resolvine, Protectine und Maresine. Deren Wirkung basiert nicht zuletzt auf einer aktiven Abregulation entzündlicher Prozesse. Damit haben sich die Omega-3-Fettsäuren zu einem wichtigen Bestandteil der orthomolekularen Diagnostik und Therapie entwickelt.

Schlüsselwörter

Omega-6-Fettsäuren - Omega-3-Fettsäuren - Eicosanoide - Lipoxine - Resolvine

• Literatur

• 1 Aoki H, Hisada T, Ishizuka T et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008; 367: 509-515
• 2 Arita M, Yoshida M, Hong S et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. PNAS 2005; 102: 7671-7676
• 3 Arm JP, Horton CE, Mencia-Huerta JM et al. Effect of dietary supplementation with fish oil lipids on mild asthma. Thorax 1988; 43: 84-92
• 4 Bang S, Yoo S, Yang TJ et al. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol 2012; 165: 683-692
• 5 Bjerve KS, Mostad IL, Thoresen L. Alpha-linolenic acid deficiency in patients on long-term gastric tube feeding: Estimation of linolenic acid and long-chain unsaturated n-3 fatty acid requirement in man. Am J Clin Nutr 1987; 45: 66-77
• 6 Bjerve KS, Thoresen L, Børsting S. Linseen and cod liver oil induce rapid growth in a 7-year-old girl with n-3 fatty acid deficiency. J Parenter Enter Nutr 1988; 12: 521-525
• 7 Burr GO, Burr MM. A new deficiency disease produced by rigid exclusion of fat from the diet. J Biol Chem 1929; 82: 345-367
• 8 Butovich IA. On the structure and synthesis of neuroprotectin D1, a novel anti-inflammatory compound of the docosahexaenoic acid family. J Lipid Res 2005; 46: 2311-2314
• 9 Fredman G, Van Dyke TE, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 2010; 30: 2005-2013
• 10 Gonzalez-Periz A, Horrillo R, Ferré N et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23: 1946-1957
• 11 Harbige LS. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 2003; 38: 323-341
• 12 Hudert CA, Weylandt KH, Lu Y et al. Transgenic mice rich in omega-3 fatty acids are protected from colitis. PNAS 2006; 103: 11276-11281
• 13 Kennedy AD, DeLeo FR. Neutrophil apoptosis and the resolution of infection. Immunol Res 2009; 43: 25-61
• 14 Kremer JM, Jubiz W, Michalek A et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, cross study. Ann Intern Med 1987; 106: 497-503
• 15 Li N, He J, Schwartz CE et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther 2010; 26: 431-439
• 16 Marchioli R, Avanzini F, Barzi F et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations. GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22: 2085-2103
• 17 Perretti M, D‘Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009; 9: 62-70
• 18 Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21: 325-332
• 19 Serhan CN, Clish CB, Brannon J et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-1204
• 20 Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. PNAS 1984; 81: 5335-5339
• 21 Serhan CN, Yang R, Martinod K et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15-23
• 22 Simmons DL, Botting RM, Hla T. Cyclooxgenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437